Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05319093 · ClinicalTrials.gov registry record
Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients
A clinical trial, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- 26
- Enrollment target
NCT05319093: Clinical Trial study, sponsored by Brigham and Women's Hospital.
NCT05319093 is a clinical trial that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05319093 was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
Multi-center observational study to assess the short-term response of multiple sclerosis (MS) patients initiated on Ozanimod with respect to fatigue. Patterns of brain changes on brain magnetic resonance imaging (MRI) that might modulate the effect of Ozanimod treatment on fatigue will also be assessed.
Primary Outcome
Difference in Modified Fatigue Impact Scale (MFIS) score between baseline (treatment initiation) and month 3. MFIS score will be assessed at baseline, as well as on days 28, 56 and 84 of the trial period. Should the 84-day measurement not be available, the three-months change will be estimated by linear regression extrapolation using available measurements.
Interventions
- DRUG Ozanimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2024-07-23 |
Why NCT05319093 stopped before completion
NCT05319093 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Ozanimod is the first listed.
NCT05319093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05319093 about?
NCT05319093 is a clinical study titled "Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients". Multi-center observational study to assess the short-term response of multiple sclerosis (MS) patients initiated on Ozanimod with respect to fatigue. Patterns of brain changes on brain magnetic resonance imaging (MRI) that might modulate the effect of Ozanimod treatment on fatigue will also be asses...
What is the current status of trial NCT05319093?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 2022-04-01. Estimated completion is 2024-07-23.
What interventions are being tested in trial NCT05319093?
The interventions under investigation include: Ozanimod (DRUG).
Who is sponsoring clinical trial NCT05319093?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI